Alpha Compute Corp

NasdaqCM:ALP Stock Report

Market Cap: US$5.7m

Alpha Compute Past Earnings Performance

Past criteria checks 0/6

Alpha Compute's earnings have been declining at an average annual rate of -19.5%, while the Biotechs industry saw earnings growing at 36.2% annually.

Key information

-19.46%

Earnings growth rate

-11.43%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equity-167.67%
Net Marginn/a
Last Earnings Update30 Sep 2025

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Aug 29

Portage Biotech GAAP EPS of -$0.13

Portage Biotech press release (NASDAQ:PRTG): Q1 GAAP EPS of -$0.13. As of June 30, 2022, the Company had cash and cash equivalents of approximately $21.2 million.
Seeking Alpha • Jul 20

Portage Biotech rises after getting full ownership of its anti-cancer agonist platform

Portage Biotech (NASDAQ:PRTG) stock has added 16.8% to $10.95 in Wednesday morning trading, after the company said it had acquired the remaining ownership interest in its invariant natural killer T cell (iNKT cell) agonist platform. iNKT cells play an important role in anti-tumor immune responses. PRTG's synthetic iNKT agonists activate and expand important immune system components and immune attacks against cancer. With the acquisition of the about 22% remaining ownership interest, PRTG now fully owns the worldwide rights to its iNKT agonists, including lead programs PORT-2 and PORT-3. The acquisition was done through PRTG's unit iOx Therapeutics from the founding equity holders in exchange for 1.07M shares of Portage (PRTG). Additionally, a payment of $25M in PRTG shares or cash would be triggered upon the achievement of a certain clinical milestone in the PORT-2 or PORT-3 programs.
Seeking Alpha • Jul 06

Portage Biotech acquires Tarus Therapeutics, a developer of adenosine receptor antagonists

Portage Biotech (NASDAQ:PRTG) on Wednesday said it would acquire privately-held Tarus Therapeutics in exchange for about 2.4M PRTG shares and the assumption of $3M in liabilities. The acquisition of Tarus allows PRTG to acquire two clinical-stage adenosine compounds and two preclinical assets for a ~$21M upfront consideration. The deal also calls for additional payments of up to $32M in PRTG shares or cash upon achievement of certain milestones. As per the deal, Robert Glassman, a former independent director of Tarus, will join PRTG's board. PRTG also said it had entered into a committed share purchase agreement for up to $30M with Chicago-based institutional investor Lincoln Park Capital Fund LLC, the proceeds of which will potentially extend PRTG's cash runway into 2024. PRTG stock earlier closed +2.5% at $7.72.

Revenue & Expenses Breakdown

How Alpha Compute makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:ALP Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 250-1572
30 Jun 250-1152
31 Mar 250-743
31 Dec 240-3054
30 Sep 240-6757
30 Jun 240-71610
31 Mar 240-75613
31 Dec 230-145613
30 Sep 230-113613
30 Jun 230-109610
31 Mar 230-10579
31 Dec 220-1788
30 Sep 220-1497
30 Jun 220-1697
31 Mar 220-1797
31 Dec 210-211010
30 Sep 210-1988
30 Jun 210-1868
31 Mar 210-1657
31 Dec 200-623
30 Sep 200-624
30 Jun 200-524
31 Mar 200-524
31 Dec 190-625
30 Sep 190-524
30 Jun 190-413
31 Mar 190-312
31 Dec 18012410
30 Sep 18012410
30 Jun 18012410
31 Mar 18012411
31 Dec 170-10129
30 Sep 170-16129
30 Jun 17019129
31 Mar 17016332
31 Dec 1602425
30 Sep 1602767
30 Jun 160-868
31 Mar 160-655
31 Dec 150-654
30 Sep 150-313

Quality Earnings: ALP is currently unprofitable.

Growing Profit Margin: ALP is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ALP is unprofitable, and losses have increased over the past 5 years at a rate of 19.5% per year.

Accelerating Growth: Unable to compare ALP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: ALP has a negative Return on Equity (-167.67%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/15 09:17
End of Day Share Price 2026/06/12 00:00
Earnings2025/09/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alpha Compute Corp is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin WalshB. Riley Securities, Inc.
Li Wang WatsekCantor Fitzgerald & Co.
Kevin DedeH.C. Wainwright & Co.